KR20100028537A - 사이클로덱스트린을 사용하여 플로르페니콜 및 구조적으로 관련된 항생제의 용해도를 증진시키기 위한 화합물 및 방법 - Google Patents

사이클로덱스트린을 사용하여 플로르페니콜 및 구조적으로 관련된 항생제의 용해도를 증진시키기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20100028537A
KR20100028537A KR1020097024467A KR20097024467A KR20100028537A KR 20100028537 A KR20100028537 A KR 20100028537A KR 1020097024467 A KR1020097024467 A KR 1020097024467A KR 20097024467 A KR20097024467 A KR 20097024467A KR 20100028537 A KR20100028537 A KR 20100028537A
Authority
KR
South Korea
Prior art keywords
composition
cyclodextrin
florfenicol
weight percent
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097024467A
Other languages
English (en)
Korean (ko)
Inventor
세레나 통기아니
키이쓰 앨런 프리호프
Original Assignee
쉐링-프라우 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링-프라우 리미티드 filed Critical 쉐링-프라우 리미티드
Publication of KR20100028537A publication Critical patent/KR20100028537A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020097024467A 2007-04-27 2008-04-23 사이클로덱스트린을 사용하여 플로르페니콜 및 구조적으로 관련된 항생제의 용해도를 증진시키기 위한 화합물 및 방법 Withdrawn KR20100028537A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91437607P 2007-04-27 2007-04-27
US60/914,376 2007-04-27

Publications (1)

Publication Number Publication Date
KR20100028537A true KR20100028537A (ko) 2010-03-12

Family

ID=39619330

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097024467A Withdrawn KR20100028537A (ko) 2007-04-27 2008-04-23 사이클로덱스트린을 사용하여 플로르페니콜 및 구조적으로 관련된 항생제의 용해도를 증진시키기 위한 화합물 및 방법

Country Status (14)

Country Link
US (1) US20090062397A1 (enExample)
EP (1) EP2150245A1 (enExample)
JP (1) JP2010525059A (enExample)
KR (1) KR20100028537A (enExample)
CN (1) CN101686956A (enExample)
AR (1) AR066265A1 (enExample)
BR (1) BRPI0810601A2 (enExample)
CA (1) CA2685264A1 (enExample)
CL (1) CL2008001194A1 (enExample)
MX (1) MX2009011642A (enExample)
PE (1) PE20090234A1 (enExample)
RU (1) RU2009143731A (enExample)
TW (1) TW200908955A (enExample)
WO (1) WO2008133901A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146351A (en) 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
CN101600686A (zh) * 2006-12-13 2009-12-09 先灵-普劳有限公司 氯霉素、甲砜霉素及其类似物的水溶性前药
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
JP2011529895A (ja) * 2008-07-30 2011-12-15 インターベツト・インターナシヨナル・ベー・ベー フロルフェニコール中間体として有用なオキサゾリン保護アミノジオール化合物を調製する方法
JP5826473B2 (ja) * 2010-09-16 2015-12-02 協和発酵バイオ株式会社 直打用高単位グルコサミン顆粒
CN102160854A (zh) * 2011-04-15 2011-08-24 广东养宝生物制药有限公司 一种包合环糊精的氟苯尼考速释型水溶性粉末制剂及其制备方法
CN102688197A (zh) * 2012-06-07 2012-09-26 湖州爱宝莱动物药业有限公司 一种氟苯尼考水溶颗粒及其制备方法
CN102813627A (zh) * 2012-09-19 2012-12-12 上海同仁药业有限公司 一种氟苯尼考可溶性粉剂的制备方法
CN104667291A (zh) * 2013-12-03 2015-06-03 中牧实业股份有限公司黄冈动物药品厂 一种改进的氟苯尼考包合物的制备方法
CN104800167B (zh) * 2015-04-22 2018-04-10 河南牧翔动物药业有限公司 一种氟苯尼考可溶性粉及其制备方法
CN105055319B (zh) * 2015-07-22 2018-04-10 浙江大飞龙动物保健品有限公司 一种氟苯尼考可溶性粉及其制备方法
CN105079818B (zh) * 2015-08-31 2018-04-20 王玉万 用乙酰胺和环糊精制备氟苯尼考可溶性粉
CN105477642B (zh) * 2015-12-15 2019-08-06 中牧南京动物药业有限公司 一种高生物利用度的氟苯尼考组合物及其制备方法
CN106177983A (zh) * 2016-08-03 2016-12-07 佛山科学技术学院 一种氟苯尼考‑β‑环糊精包合物及其制备方法
CN107519135A (zh) * 2017-09-30 2017-12-29 中牧实业股份有限公司黄冈动物药品厂 一种高水溶型氟苯尼考粉的制备方法
CN109602916A (zh) * 2018-12-13 2019-04-12 广东温氏大华农生物科技有限公司 一种氟苯尼考包合物及其制备方法
CN111374949A (zh) * 2018-12-29 2020-07-07 西安市昌盛动物保健品有限公司 一种氟苯尼考可溶性粉或溶液的制备工艺
CN110279664B (zh) * 2019-07-30 2021-09-03 四川农业大学 一种氟苯尼考包合物冻干粉针剂及其制备方法
CN112535663A (zh) * 2019-09-23 2021-03-23 江西邦诚动物药业有限公司 一种速溶固体分散氟苯尼考粉及其制备方法
CN110787131B (zh) * 2019-12-13 2022-04-01 河北远征药业有限公司 一种氟苯尼考可溶性粉制剂的制备方法
CN112190551A (zh) * 2020-11-20 2021-01-08 湖北龙翔药业科技股份有限公司 一种氟苯尼考可溶性粉及其制备方法
CN112675315A (zh) * 2021-01-05 2021-04-20 佛山科学技术学院 一种γ-环糊精-替米考星包合物及其制备方法和应用
CN112716902B (zh) * 2021-02-04 2021-10-12 广州市和生堂动物药业有限公司 一种氟苯尼考粉及其制备方法
CN112641730A (zh) * 2021-02-19 2021-04-13 山东鲁抗舍里乐药业有限公司高新区分公司 一种可溶氟苯尼考粉的制备方法
CN113230233A (zh) * 2021-05-14 2021-08-10 中国农业科学院兰州畜牧与兽药研究所 一种氟苯尼考固体分散包合微囊及其制备方法与应用
CN114272213B (zh) * 2021-12-28 2023-10-10 厦门惠盈动物药业有限公司 一种氟苯尼考粉及其制备方法
CN114209656B (zh) * 2021-12-31 2023-08-01 浙江金朗博药业有限公司 一种氟苯尼考可溶性粉及其制备方法
CN119385937B (zh) * 2024-11-20 2025-07-15 山东金瑞生物科技有限公司 一种兽用氟苯尼考溶液及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES488154A0 (es) * 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
IT1173213B (it) * 1984-02-03 1987-06-18 Zambon Spa Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi
US5105009A (en) * 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
US5332835A (en) * 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US4582918A (en) * 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4973750A (en) * 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US5227494A (en) * 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
EP0443381B2 (en) * 1990-02-14 1997-10-22 Takeda Chemical Industries, Ltd. Effervescent composition, its production and use
NZ250394A (en) * 1990-10-25 1994-10-26 Schering Corp Fluorinated and hydroxylated oxazoline compounds
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CN1459282A (zh) * 2003-05-29 2003-12-03 季华 水溶性氟苯尼考的生产方法

Also Published As

Publication number Publication date
TW200908955A (en) 2009-03-01
MX2009011642A (es) 2010-01-29
WO2008133901A1 (en) 2008-11-06
JP2010525059A (ja) 2010-07-22
US20090062397A1 (en) 2009-03-05
RU2009143731A (ru) 2011-06-10
EP2150245A1 (en) 2010-02-10
PE20090234A1 (es) 2009-04-02
CA2685264A1 (en) 2008-11-06
CL2008001194A1 (es) 2008-11-03
CN101686956A (zh) 2010-03-31
AR066265A1 (es) 2009-08-05
BRPI0810601A2 (pt) 2014-10-21

Similar Documents

Publication Publication Date Title
KR20100028537A (ko) 사이클로덱스트린을 사용하여 플로르페니콜 및 구조적으로 관련된 항생제의 용해도를 증진시키기 위한 화합물 및 방법
US7968599B2 (en) Fast release solid formulation, preparation and use thereof
KR101354093B1 (ko) 티게사이클린 조성물 및 이의 제조방법
KR20090090387A (ko) 음료수 시스템 내에 추가하기 위한 플로르페니콜의 비등성 제형
JP6063123B2 (ja) 抗菌性組成物
JP5823093B2 (ja) 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
Szejtli Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: therefore the increase in number of marketed drug/cyclodextrin formulations is so slow
KR20040106452A (ko) 아미오다론 및 설포알킬 에테르 사이클로덱스트린을함유하는 제제
WO2001041757A1 (en) Cyclodextrin-containing pharmaceutical composition
EA034430B1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
WO2017127835A2 (en) Aqueous formulations and methods of preparation and use thereof
CN111093625A (zh) 达托霉素制剂
WO2018091668A1 (en) Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US7259153B2 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
EP3873529A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
KR20200059221A (ko) 시포니모드를 포함하는 비경구 제형
PT89301B (pt) Processo para a preparacao de composicoes aquosas que contem um derivado do acido piperridinil-ciclo-pentil-heptenoico
US20170368055A1 (en) Methods for treating infections

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid